MARCY L'ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM)
bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008.
Net sales amounted to €528.2 million in the first half of 2008, an increase of 7.6% at constant exchange rates and scope of consolidation (like-for-like) over the first six months of 2007. Including the 1.4% growth generated by the business development agreements, the increase amounted to 9%.
In the second quarter, net sales were up 9.1% like-for-like over the year-earlier period.
bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008.
Net sales amounted to €528.2 million in the first half of 2008, an increase of 7.6% at constant exchange rates and scope of consolidation (like-for-like) over the first six months of 2007. Including the 1.4% growth generated by the business development agreements, the increase amounted to 9%.
In the second quarter, net sales were up 9.1% like-for-like over the year-earlier period.
